HanchorBio Showcases FBDB™ Platform and Global Strategy at BIO Asia-Taiwan 2026

BIO Asia-Taiwan Exhibition 2026 takes place from July 16 to 19 at the Taipei Nangang Exhibition Center. HanchorBio (TPEx: 7827), a global clinical-stage biotechnology company, expands its presence at this year’s event to display its proprietary “Fc-Based Designer Biologics” (FBDB™) platform. Chief Scientific Officer Dr. Wenwu Zhai will host a company presentation on July 17 to detail HanchorBio’s research pipeline, clinical advancements, and commercial strategy. 

During the 4-day exhibition, the company will also schedule multiple one-on-one business networking sessions to facilitate active exchanges with several major Japanese pharmaceutical companies and potential overseas partners.

AI-Guided Design Drives Myeloid-Enhancer Strategy

The FBDB™ platform links various immunomodulatory molecules, cytokines, or cytokine traps onto the Fc backbone of an antibody to create multi-functional fusion proteins with differentiated mechanisms of action. The platform currently supports over eight candidate drugs targeting solid tumors, hematologic malignancies, and autoimmune diseases. By activating both innate and adaptive immune systems, HanchorBio aims to improve tumor clearance and overcome the limitations of current immunotherapies.  

The company actively applies AI-guided design to accelerate development and differentiate its clinical strategy. For example, the R&D team engineered the clinical-stage asset HCB101 to maintain its binding affinity for CD47 on tumor cells while minimizing interactions with normal red blood cells. Through AI-assisted protein engineering and structural analysis, the team identified key binding sites between SIRPα and CD47 and predicted how different SIRPα variants would affect binding capacity. A rigorous screening process then eliminated molecules prone to binding to red blood cells. This approach allows HCB101 to avoid the hematologic toxicities frequently observed in earlier CD47-targeting therapies while showing early signs of efficacy.

HanchorBio leverages this AI-driven strategy to establish its novel “Myeloid-Enhancer” platform. Moving beyond a sole reliance on T-cell-based therapies, the company aims to strengthen the synergistic mechanisms driven by macrophages and innate immunity. This approach aims to fundamentally reshape the immunosuppressive tumor microenvironment and unlock new therapeutic options for difficult-to-treat solid tumors.

Implementing the Anchor-and-Expand Clinical Strategy

HanchorBio currently conducts multi-center clinical trials in the United States, mainland China, and Taiwan. The company’s fusion protein candidates, HCB101 and HCB301, have advanced to Phase 1b/2a and Phase 1, respectively.

For its core asset HCB101, HanchorBio adopts an “anchor-and-expand” strategy. The company targets second-line gastric cancer as the leading clinical anchor to validate the drug’s anti-tumor activity. HanchorBio plans to subsequently expand the treatment scope to pancreatic cancer, cholangiocarcinoma, diffuse-type gastric cancer, and other stroma-rich, myeloid-dominant tumors. HCB101 also functions as the clinical SIRPα backbone for the FBDB™ platform, generating multi-functional fusion proteins such as HCB301 (incorporating TGFβ modulation) and HCB303 (incorporating TIGIT modulation).

Preliminary efficacy data for HCB101, presented via a clinical poster at the exhibition, reveal encouraging results in second-line gastric and gastroesophageal junction (GEJ) cancers. In the mid-dose cohort, efficacy-evaluable patients achieved a 100% disease control rate (DCR) and a confirmed objective response rate (ORR) of 80%, with multiple individuals showing significant tumor shrinkage. Additionally, clinical assessments in head and neck squamous cell carcinoma (HNSCC) demonstrated a 100% DCR and a 50% confirmed ORR within the low-dose cohort, which included a reported complete response (CR) case. These findings highlight the strong therapeutic potential of HCB101 across various cancer types.

Partnering With Investors and Strategic Allies to Accelerate Commercialization of Innovative Biologics

International investment and strategic partnerships drive the globalization of biopharma companies. In light of this, HanchorBio actively pursues international expansion through innovative drug R&D, multi-national and multi-center clinical trials, global licensing, and funding from specialized biotech and healthcare funds.

In June 2025, HanchorBio finalized its first international out-licensing agreement, partnering with Shanghai Henlius Biotech in a deal valued at $202 million. Under this agreement, Henlius receives exclusive rights to develop, manufacture, and commercialize HCB101 across Greater China, key Southeast Asian countries, and the Middle East and North Africa (MENA) region. This agreement validates the commercial viability of the FBDB™ platform. Then, in early July 2026, HanchorBio announced a strategic collaboration with InxMed. The two companies will evaluate HCB101 in combination with InxMed’s novel FAK inhibitor and FAK-targeted ADC to explore new therapeutic options for difficult-to-treat fibrotic solid tumors.

Regarding capital market milestones, HanchorBio registered on the Emerging Stock Board in June 2025 and subsequently listed on the Taiwan Innovation Board (TIB) in May 2026. Prior to this listing, the company drew substantial interest from both domestic and international institutional investors, ultimately securing global healthcare investment firm OrbiMed as a strategic shareholder.

The 2026 edition is HanchorBio’s first BIO Asia-Taiwan Exhibition following its TIB listing. During the exhibition, the company has also scheduled multiple one-on-one business matchmaking sessions to engage with several major Japanese pharma companies and potential partners worldwide. 

Moving forward, HanchorBio will actively explore opportunities for product licensing, co-development, and other strategic collaborations to continue expanding the global partnership network for its FBDB™ platform and its core clinical pipeline. 

HanchorBio at BIO Asia-Taiwan 2026 Exhibition

• Booth Location: Booth L221, 4F, Taipei Nangang Exhibition Center, Hall 1  
• Company Presentation: Friday, July 17, 15:45–16:00 
• Presentation Venue: Booth N913, 4F, Taipei Nangang Exhibition Center, Hall 1  
• Speaker: Dr. Wenwu Zhai, Chief Scientific Officer, HanchorBio 

Author

Richard Chau